reports
Soleno Therapeutics Announces Retirement of James Mackaness and Appoin...
Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness, who announced that he will be retiring from the Company by the end of the first quarter. Mr. Mackaness will serve as a consultant to Soleno through the end of the year t...
Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financia...
Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on the U.S. launch of VYKAT™ XR (diazoxide choline) extended-release tablets. Fourth Quarter and Full-Year 2025 and Recent Corporate Highlights Rev...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Dollar General Corporation and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 12 February 2026 in which we reassessed the appropriateness of the ratings in th...
Design Therapeutics to Participate in Upcoming Investor Conferences
Design Therapeutics to Participate in Upcoming Investor Conferences CARLSBAD, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will present at the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026, at 1:20 p.m. ET (virtual)Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026, at 2:20 p.m. ET in Miami, FL Live webcasts...
Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financ...
Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET REDWOOD CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its fourth quarter and full-year 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, February 25, 2026. The Company will host a conference call and webcast at 4:30 PM East...
SurancePlus Reports Solid Results & Announces Launch of This Year’s Of...
SurancePlus Reports Solid Results & Announces Launch of This Year’s Offering GRAND CAYMAN, Cayman Islands, Feb. 10, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: ), (the “Company”), a leader in digitizing reinsurance securities as tokenized real-world assets (RWAs), together with its subsidiary , today announced the commencement of its 2026-27 offering of participation shares represented by digital tokens with targeted annual returns of 20% and 42%. The participation shares will be represented by digital tokens labelled “T20-2027” and “T42-2027”, representing our Balanced-Yield and High-Yield partic...
Soleno Therapeutics to Participate in Upcoming Conferences
Soleno Therapeutics to Participate in Upcoming Conferences REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February and March: Guggenheim Emerging Outlook: Biotech Summit 2026Presentation Date: Thursday, February 12, 2026 at 11:30 AM ETPresentation Format: Fireside ChatWebcast: Oppenheimer 36th Annual Healthcare Life Sciences ConferencePresentation Date...
Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Fu...
Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results REDWOOD CITY, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced select preliminary financial and operating results for the fourth quarter and full-year 2025: Preliminary unaudited full-year 2025 net revenue related to U.S. sales of VYKAT™ XR since second quarter launch expected to be in a range of $189 million to $191 million.Preliminary unaudited ...
Soleno Therapeutics Announces Publication of Results from Pivotal Stud...
Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT™ XR in the Journal of Clinical Endocrinology and Metabolism REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced a publication in the peer-reviewed Journal of Clinical Endocrinology and Metabolism (JCEM). The paper, titled, “Diazoxide Choline Extended-Release Tablets in Prader-Willi Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Withdraw...
Dollar General Corp: 2 directors
Two Directors at Dollar General Corp sold/sold after exercising options 9,782 shares at between 133.355USD and 134.890USD. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by al...
Oxbridge / SurancePlus and Alphaledger Announce Partnership to Bring R...
Oxbridge / SurancePlus and Alphaledger Announce Partnership to Bring RWA High-Yield Tokenized Reinsurance to the Solana Ecosystem GRAND CAYMAN, Cayman Islands, Dec. 11, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ), (the “Company”), a leader in digitizing reinsurance securities as tokenized real-world assets (RWAs), together with its subsidiary , today announced a strategic partnership with , a leading developer of RWA (Real World Assets) -native tokenized securities infrastructure. The partnership, formally unveiled at , marks first official entry into the ecosystem, bringing one of the world’...
Soleno Therapeutics Announces the Passing of Board Member William G. H...
Soleno Therapeutics Announces the Passing of Board Member William G. Harris REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today regrets to announce the passing of William G. “Bill” Harris, who served as a valued member of Soleno’s Board of Directors since June 2014. Mr. Harris also served as Chairman of the Audit Committee. “I have known Bill for many years, and always viewed him as a person of integrity, who exhibited pragmatism and a...
Oxbridge / SurancePlus to Attend Abu Dhabi Finance Week (ADFW) and Sol...
Oxbridge / SurancePlus to Attend Abu Dhabi Finance Week (ADFW) and Solana Breakpoint 2025 GRAND CAYMAN, Cayman Islands, Dec. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ), (the “Company”), a leader in digitizing reinsurance securities as tokenized real-world assets (RWAs), together with its subsidiary , today announced that the Company will be attending a series of premier global events in Abu Dhabi next week - bringing together the world’s largest financial institutions, capital allocators, and blockchain innovators. These engagements support mission to expand institutional access to tokeniz...
Design Therapeutics to Participate in Upcoming Investor Conferences
Design Therapeutics to Participate in Upcoming Investor Conferences CARLSBAD, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in fireside chats at the following upcoming investor conferences: Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025, at 3:30 p.m. ET in New York, NYEvercore 8th Annual Healthcare Conference on Thursday, December 4, 2025, at 10:00 a.m. ET in Coral Gab...
Soleno Therapeutics to Present at the Piper Sandler 37th Annual Health...
Soleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference REDWOOD CITY, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 37th Healthcare Conference on Thursday, December 4, 2025, at 9:00 AM Eastern Time. A and replay of the presentation will be available in the Investors section on the Company’s we...
Soleno Therapeutics Announces Entry Into $100 Million Accelerated Shar...
Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement REDWOOD CITY, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that its Board of Directors has authorized a share repurchase and that it has entered into an Accelerated Share Repurchase Agreement (“ASR”) with Jefferies LLC (“Jefferies”) to repurchase $100 million of Soleno’s common stock. “These actions demonstrate our confidence in our commer...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
ATNI ATN INTERNATIONAL INC.
35G GENPACT LIMITED
EXPE EXPEDIA GROUP INC.
CRK COMSTOCK RESOURCES INC.
AXTI AXT INC.
ALB ALBEMARLE CORPORATION
ACRE ARES COMMERCIAL REAL ESTATE
AGO ASSURED GUARANTY LTD.
HRTG HERITAGE INSURANCE HOLDINGS INC.
DRH DIAMONDROCK HOSPITALITY COMPANY
ELY CALLAWAY GOLF COMPANY
FLGT FULGENT GENETICS
DK DELEK US HOLDINGS INC
TALO TALOS ENERGY INC.
LASR NLIGHT
GLOB GAZIT-GLOBE LTD.
ARVN ARVINAS HOLDING
PLMR PALOMAR HOLDINGS
BW BABCOCK & WILCOX ENTERPRISES
TXG 10X GENOMICS INC CLASS A
PGNY PROGYNY
AMPY AMPLIFY ENERGY
EOSE EOS ENERGY ENTERPRISES INC (A)
MSGE MADISON SQUARE GARDEN ENTERTAINMENT
DOCN DIGITALOCEAN HLDGS INC
DSGN DESIGN THERAPEUTICS INC
FIGS FIGS INC
YOU ONTO INNOVATION INC.
PPTA CLEAR SECURE INC
AMPX PERPETUA RESOURCES CORP
OS AMPRIUS TECHNOLOGIES INC
SNDK ONESTREAM INC
CSIOX SANDISK CORP
BALY CATALYST PERINI STRATEGIC INCOM ORD
HOII BALLY'S CORPORATION
REX HOOD GROWTH & INCOME ETF
Oxbridge Highlights 2025/26 Contract Performance Updates and Reports Q...
Oxbridge Highlights 2025/26 Contract Performance Updates and Reports Q3 2025 Results GRAND CAYMAN, Cayman Islands, Nov. 06, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ), (the “Company”), a leader in digitizing reinsurance securities as tokenized real-world assets (RWAs), together with its subsidiary , today reported its results for the three and nine months ended September 30, 2025. SurancePlus 2025–2026 Tokenized Reinsurance Update continues to demonstrate strong performance across its 2025–2026 tokenized reinsurance offerings. The Balanced Yield Token (EtaCat Re), which targeted a 20% annual...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.